Lipella Pharmaceuticals Announces U.S. Patent Allowance for Innovative Liposomal Drug Delivery Platform
October 15, 2024 05:00 ET
|
Lipella Pharmaceuticals Inc.
Lipella Pharmaceuticals Announces U.S. Patent Allowance for Innovative Liposomal Drug Delivery Platform
GEn1E Lifesciences Publishes Breakthrough Research Unveiling Novel Mechanism of Action of Dual Signal Modulators for Anti-inflammatory and Endothelial-Stabilizing Therapies
October 14, 2024 06:02 ET
|
GEn1E Lifesciences Inc.
GEn1E Lifesciences today announced the publication of a landmark study in the prestigious Journal of Pharmacology and Experimental Therapeutics (JPET)
Lipella Pharmaceuticals to Participate at H.C. Wainwright's 26th Annual Global Investment Conference in New York
August 27, 2024 08:00 ET
|
Lipella Pharmaceuticals Inc.
Lipella Pharmaceuticals to Participate at H.C. Wainwright's 26th Annual Global Investment Conference in New York
Kaerus Bioscience Announces Initiation of Phase 1 Clinical Trial for its Novel BK Channel Modulator KER-0193 being developed for Fragile X Syndrome
July 25, 2024 05:00 ET
|
Kaerus Bioscience
LONDON, July 25, 2024 (GLOBE NEWSWIRE) -- Kaerus Bioscience Ltd. (www.kaerusbio.com), a clinical-stage biotechnology company focused on developing therapeutics for rare genetic syndromes of...
Global Sodium Channel Blockers Market to Reach US$ 9.96 Billion by 2030, Rising at a CAGR of 8.5% | Report by CoherentMI
March 07, 2024 08:11 ET
|
CMI
Burlingame, March 07, 2024 (GLOBE NEWSWIRE) -- CoherentMI published a report, titled, Global Sodium Channel Blockers Market was valued at US$ 5.64 Billion in the year 2023 and is anticipated to...
Revolution Medicines to Report Financial Results for Fourth Quarter and Full Year 2023 After Market Close on February 26, 2024
February 20, 2024 16:05 ET
|
Revolution Medicines, Inc.
REDWOOD CITY, Calif., Feb. 20, 2024 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing novel targeted therapies for RAS-addicted cancers,...
Botulinum Toxins Market to Reach USD 11.5 billion by 2031, Growing at a CAGR of 7.5%| Transparency Market Research, Inc.
January 09, 2024 02:29 ET
|
Transparency Market Research
Wilmington, Delaware, United States, Jan. 09, 2024 (GLOBE NEWSWIRE) -- Transparency Market Research Inc. - The botulinum toxin market generated US$ 6.1 billion in sales in 2022. The market is...
QSAM Biosciences Signs Term Sheet to be Acquired by Telix Pharmaceuticals; Receives $2 Million Pre-Closing Collaboration and Option Fee
November 14, 2023 07:30 ET
|
QSAM Biosciences Inc.
Austin, TX, Nov. 14, 2023 (GLOBE NEWSWIRE) -- QSAM Biosciences Inc. (OTCQB: QSAM), a company developing therapeutic radiopharmaceuticals for the treatment of primary and secondary bone cancer and...
Interpace Biosciences Announces Record Third Quarter 2023 Financial and Business Results
November 08, 2023 15:29 ET
|
Interpace Biosciences, Inc.
●Q3 Revenue of $9.1 million; an 11% increase year-over-year ●Q3 Test volume up 11% year-over-year ●Q3 Reimbursement improvement up 11% year-over-year, driven by additional commercial contracts and...
Neurotoxin Market to Hit US$ 13.3 billion by 2031, Growing at a CAGR of 6.8 % | Says Transparency Market Research Inc.
November 01, 2023 12:00 ET
|
Transparency Market Research
Wilmington, Delaware, United States, Nov. 01, 2023 (GLOBE NEWSWIRE) -- Transparency Market Research Inc. - The global neurotoxin market stood at US$ 7.78 billion in 2023 and is projected to reach...